貨號：GS40433

Mezagitamab (also known as TAK-079) is an investigational, fully human monoclonal antibody that targets CD38, a transmembrane glycoprotein highly expressed on plasma cells, activated lymphocytes, and certain malignant cells. As an IgG1 isotype, it is designed to engage potent effector functions including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). By binding to CD38, mezagitamab aims to deplete pathogenic plasma cells and activated immune cells. It is being developed for the treatment of autoimmune diseases where these cell types play a key role, such as immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), as well as for multiple myeloma.